Skip to Content
15

BD

Courtesy of BD

    A frontline fighter in the war against microbes.

    The bugs that make us sick are increasingly resistant to the drugs we’ve used (and misused) to fight them. By one estimate, antimicrobial resistance (AMR) will cause the deaths of 10 million people annually by 2050. BD’s products, including its test to rapidly detect drug-resistant tuberculosis and its infection-prevention equipment, are tools to combat AMR. BD also trains health workers to quickly and precisely diagnose and treat infection. In Uganda, with BD’s help, turnaround time for a TB test has fallen from three weeks to three days, reducing chances that a patient will go untreated or be given the wrong drug.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Country
    U.S.
    Headquarters
    Franklin Lakes, N.J.
    Impact Segment
    Public Health/Nutrition
    Sector
    Healthcare
    Industry
    Medical Products and Equipment
    CEO
    Vincent Forlenza
    Websitehttp://www.bd.com
    Company Type
    Public
    Ticker
    BDX
    Prior Year Rank-
    Revenues ($M) (Last Fiscal Year)$15,983
    Profits ($M) (Last Fiscal Year)$311
    Market Value ($M) as of 8/12/19$67,262
    Employees76,032

    Refinitiv Sustainable Leadership Monitor